← Back to headlines
Neurocrine to Acquire Soleno for Relentless Hunger Disorder Drug
Neurocrine Biosciences announced plans to acquire Soleno Therapeutics, aiming to secure a drug designed to treat a relentless hunger disorder.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Philippine Lawmaker Proposes VAT Cut Amid Fuel Crisis
just now
Ukraine's Fight to Prevent Financial Crisis: Military Levy to Be Paid Even After the War Ends
just now
JPMorgan says Anthropic's groundbreaking cybersecurity model positive for these two stocks
23m ago
Global economy shows more resilience to oil shocks - BofA
25m ago